Summary

China Hepatitis B Treatment Market Research Report by Drug Class (Nucleoside Analogues, Nucleotide Analogues, Interferons, Others), by Age Group (Adults, Pediatric), by Route of Administration (Oral, Parenteral), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Forecast till 2035

The China Hepatitis B Treatment Market report is projected to grow from USD 249.56 million in 2025 to USD 515.93 million by 2035, reflecting a 7.56% CAGR during the forecast period. The growth indicates rising demand for hepatitis B treatment and continued expansion of the market in China.

Expanding Healthcare Infrastructure
The Chinese healthcare system is constantly expanding at all levels with 1.09 million medical facilities including 38700 hospitals as well as healthcare staff coverage, all of which together contribute to greater access, more screening, diagnosis, and treatment as well as long-term management of people living with hepatitis B in this country. The high level of spending on healthcare and the insurance coverage with at least basic medical insurance covering more than 95%, support a larger use of hepatitis B treatment services.

Segment-wise Market Analysis
Drug Class
- Nucleoside Analogues: Widely used for long-term viral suppression.
- Nucleotide Analogues: Offer potent and durable antiviral activity.
- Interferons: Support immune-mediated control of hepatitis B.
- Others: Include emerging and alternative treatment options.
Age Group
- Adults: Represent the primary hepatitis B treatment population.
- Pediatric: Increasing diagnosis supports demand for pediatric therapies.
Route of Administration
- Oral: Preferred for convenient and long-term treatment.
- Parenteral: Used when injectable treatment is clinically appropriate.
Distribution Channel
- Hospital Pharmacies: Remain important for prescription-based hepatitis treatments.
- Retail Pharmacies: Provide convenient access to prescribed medicines.
- Online Pharmacies: Improve accessibility through digital medicine purchasing.

Phase 3 B-Well Milestone
In January 2026, GlaxoSmithKline (GSK) presented Phase 3 B-Well findings, the study of which, showed the primary endpoint for a functional cure of HBV. In the 2026 first quarter, the company anticipated regulatory filings as a key milestone toward advancing its hepatitis B treatment portfolio. The launch of functional cure therapy therapies is creating a new growth niche in the hepatitis B treatment market of China, beyond the traditional model of viral load suppression alone.

Shift Toward Functional Cure
Pegbing approval in October 2025 and HBsAg clearance reports may enhance demand for limited-term treatment options among those patients with HBV who achieve viral suppression and HBsAg clearance after antiviral therapy, so to say, those who have viral DNA levels undetectable and those HBsAg positive but with detectable viral DNA levels have already converted HBsAg negative but viral DNA levels have remained detected.

Key Report Attributes
- Market Size 2025: USD 249.56 Million
- Market Size 2035: USD 515.93 Million
- CAGR (2025-2035): 7.56%
- Base Year: 2024
- Market Forecast Period: 2025-2035

Industry Segmentations Growth
- By Drug Class: Nucleoside Analogues - 6.99%, Nucleotide Analogues - 8.81%.
- By Age Group: Adults - 7.96%, Pediatric - 3.16%.
- By Route of Administration: Oral - 7.22%, Parenteral - 9.45%.
- By Distribution Channel: Hospital Pharmacies - 7.73%, Retail Pharmacies - 6.05%.

Reasons to Buy
- Analyze China Hepatitis B Treatment market demand trends.
- Assess treatment needs supporting China Hepatitis B Treatment growth.
- Evaluate therapeutic innovations shaping hepatitis B treatment opportunities.
- Identify diagnostic and treatment access influencing market development.
- Understand evolving treatment strategies supporting future market expansion.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY 14
2 MARKET INTRODUCTION 16
2.1 DEFINITION 16
2.2 SCOPE OF THE STUDY 16
2.3 Research Objective 16
2.4 MARKET STRUCTURE 17
3 RESEARCH METHODOLOGY 18
3.1 Overview 18
3.2 DATA flow 20
3.2.1 DATA MINING PROCESS 20
3.3 Purchased Database: 21
3.4 Secondary Sources: 22
3.4.1 SECONDARY RESEARCH DATA FLOW: 23
3.5 Primary Research: 24
3.5.1 PRIMARY RESEARCH DATA FLOW: 25
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED 26
3.6 Approaches for market size estimation: 27
3.6.1 REVENUE ANALYSIS APPROACH 27
3.7 Data forecasting 28
3.7.1 DATA FORECASTING TYPE 28
3.8 Data modeling 29
3.8.1 MICROECONOMIC FACTOR ANALYSIS: 29
3.8.2 DATA MODELING: 30
3.9 Teams and Analyst Contribution 32
4 MARKET DYNAMICS 34
4.1 Introduction 34
4.2 Drivers 36
4.2.1 RISE IN INCIDENCE AND PREVALENCE OF HEPATITIS B 36
4.2.2 GOVERNMENT INITIATIVES AND POLICIES 36
4.2.3 ADVANCEMENTS IN TREATMENT OPTIONS 36
4.2.4 GROWING HEALTHCARE INFRASTRUCTURE 37
4.3 Restraints 38
4.3.1 LOW DIAGNOSIS AND TREATMENT COVERAGE RATES 38
4.3.2 HIGH COST OF ANTIVIRAL MEDICATIONS 38
4.3.3 SIDE EFFECTS AND TREATMENT ADHERENCE 38
4.4 Opportunities 40
4.4.1 EXPANSION OF SCREENING AND EARLY DETECTION PROGRAMS 40
4.4.2 FUNCTIONAL CURE THERAPEUTICS MARKET 40
5 MARKET FACTOR ANALYSIS 41
5.1 PORTER'S FIVE FORCES ANALYSIS 41
5.1.1 THREAT OF NEW ENTRANTS (MODERATE) 41
5.1.2 BARGAINING POWER OF SUPPLIERS (LOW) 42
5.1.3 BARGAINING POWER OF BUYERS (HIGH) 42
5.1.4 THREAT OF SUBSTITUTES (MODERATE) 42
5.1.5 COMPETITIVE RIVALRY (HIGH) 42
5.2 SUPPLY CHAIN ANALYSIS 43
6 CHINA HEPATITIS B TREATMENT MARKET, BY DRUG CLASS 45
6.1 Overview 45
7 CHINA HEPATITIS B TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 48
7.1 Overview 48
8 CHINA HEPATITIS B TREATMENT MARKET, BY AGE GROUP 50
8.1 Overview 50
9 CHINA HEPATITIS B TREATMENT MARKET, BY DISTRIBUTION CHANNEL 52
9.1 Overview 52
10 COMPETITIVE LANDSCAPE 55
10.1 Introduction 55
10.2 market share analysis, 2025 55
10.3 competitor dashboard 56
10.4 Comparative analysis: Key players financiaL 57
10.5 Key Developments 57
11 COMPANY PROFILES 58
11.1 Gilead Sciences, Inc. 58
11.1.1 COMPANY OVERVIEW 58
11.1.2 FINANCIAL OVERVIEW 59
11.1.3 PRODUCTS OFFERED 59
11.1.4 KEY DEVELOPMENTS 60
11.1.5 SWOT ANALYSIS 60
11.1.6 KEY STRATEGY 61
11.2 Bristol Myers Squibb 62
11.2.1 COMPANY OVERVIEW 62
11.2.2 FINANCIAL OVERVIEW 63
11.2.3 PRODUCTS OFFERED 63
11.2.4 KEY DEVELOPMENTS 64
11.2.5 SWOT ANALYSIS 64
11.2.6 KEY STRATEGY 65
11.3 Novartis 66
11.3.1 COMPANY OVERVIEW 66
11.3.2 FINANCIAL OVERVIEW 67
11.3.3 PRODUCTS OFFERED 67
11.3.4 KEY DEVELOPMENTS 68
11.3.5 SWOT ANALYSIS 68
11.3.6 KEY STRATEGY 69
11.4 GlaxoSmithKline (GSK plc) 70
11.4.1 COMPANY OVERVIEW 70
11.4.2 FINANCIAL OVERVIEW 71
11.4.3 PRODUCTS OFFERED 72
11.4.4 KEY DEVELOPMENTS 72
11.4.5 SWOT ANALYSIS 73
11.4.6 KEY STRATEGY 74
11.5 Amoytop Biotech Co., Ltd. 75
11.5.1 COMPANY OVERVIEW 75
11.5.2 FINANCIAL OVERVIEW 76
11.5.3 PRODUCTS OFFERED 76
11.5.4 KEY DEVELOPMENTS 77
11.5.5 SWOT ANALYSIS 77
11.5.6 KEY STRATEGY 78
11.6 Tianqing Pharmaceutical Group Co., Ltd 79
11.6.1 COMPANY OVERVIEW 79
11.6.2 FINANCIAL OVERVIEW 79
11.6.3 PRODUCTS OFFERED 80
11.6.4 KEY DEVELOPMENTS 80
11.6.5 SWOT ANALYSIS 81
11.6.6 KEY STRATEGY 82
11.7 Sino Biopharmaceutical Limited 83
11.7.1 COMPANY OVERVIEW 83
11.7.2 FINANCIAL OVERVIEW 84
11.7.3 PRODUCTS OFFERED 85
11.7.4 KEY DEVELOPMENTS 85
11.7.5 SWOT ANALYSIS 86
11.7.6 KEY STRATEGY 87
11.8 Jiangsu Hansoh Pharmaceutical Co., Ltd. 88
11.8.1 COMPANY OVERVIEW 88
11.8.2 FINANCIAL OVERVIEW 89
11.8.3 PRODUCTS OFFERED 89
11.8.4 KEY DEVELOPMENTS 90
11.8.5 SWOT ANALYSIS 90
11.8.6 KEY STRATEGY 91
11.9 AusperBio 92
11.9.1 COMPANY OVERVIEW 92
11.9.2 FINANCIAL OVERVIEW 92
11.9.3 PRODUCTS OFFERED 93
11.9.4 KEY DEVELOPMENTS 93
11.9.5 SWOT ANALYSIS 94
11.9.6 KEY STRATEGY 95
11.10 Ascletis BioScience Co., Ltd. 96
11.10.1 COMPANY OVERVIEW 96
11.10.2 FINANCIAL OVERVIEW 96
11.10.3 PRODUCTS OFFERED 97
11.10.4 KEY DEVELOPMENTS 97
11.10.5 SWOT ANALYSIS 98
11.10.6 KEY STRATEGY 99
12 DATA CITATIONS 100

COMPANIES MENTIONED
Gilead Sciences, Inc., Bristol Myers Squibb, Novartis, GlaxoSmithKline, Amoytop Biotech, Tianqing Pharmaceutical Group, Sino Biopharmaceutical Limited, Jiangsu Hansoh Pharmaceutical, Ausperbio, Ascletis BioScience Co., Ltd.

ページTOPに戻る

List of Tables/Graphs

LIST OF FIGURES
FIGURE 1 CHINA HEPATITIS B TREATMENT MARKET : STRUCTURE 17
FIGURE 2 CHINA HEPATITIS B TREATMENT MARKET: MARKET GROWTH AFFECTING FACTOR ANALYSIS (2019-2036) 35
FIGURE 3 CHINA HEPATITIS B TREATMENT MARKET DRIVER: IMPACT ANALYSIS 37
FIGURE 4 CHINA HEPATITIS B TREATMENT MARKET RESTRAINT: IMPACT ANALYSIS 39
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: CHINA HEPATITIS B TREATMENT MARKET 41
FIGURE 6 CHINA HEPATITIS B TREATMENT MARKET, DRUG CLASS SEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION) 45
FIGURE 7 CHINA HEPATITIS B TREATMENT MARKET, BY DRUG CLASS, 2025 & 2035 (USD MILLION) 46
FIGURE 8 CHINA HEPATITIS B TREATMENT MARKET SHARE (%), BY DRUG CLASS, 2025 47
FIGURE 9 CHINA HEPATITIS B TREATMENT MARKET, ROUTE OF ADMINISTRATION SEGMENT
ATTRACTIVENESS, 2025 & 2035 (USD MILLION) 48
FIGURE 10 CHINA HEPATITIS B TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2025 & 2035 (USD MILLION) 48
FIGURE 11 CHINA HEPATITIS B TREATMENT MARKET SHARE (%), BY ROUTE OF ADMINISTRATION, 2025 49
FIGURE 12 CHINA HEPATITIS B TREATMENT MARKET, AGE GROUP SEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION) 50
FIGURE 13 CHINA HEPATITIS B TREATMENT MARKET, BY AGE GROUP, 2025 & 2035 (USD MILLION) 50
FIGURE 14 CHINA HEPATITIS B TREATMENT MARKET SHARE (%), BY AGE GROUP, 2025 51
FIGURE 15 CHINA HEPATITIS B TREATMENT MARKET, DISTRIBUTION CHANNEL SEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION) 52
FIGURE 16 CHINA HEPATITIS B TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2025 & 2035 (USD MILLION) 52
FIGURE 17 CHINA HEPATITIS B TREATMENT MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2025 53
FIGURE 18 CHINA HEPATITIS B TREATMENT MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 55
FIGURE 19 COMPETITOR DASHBOARD: CHINA HEPATITIS B TREATMENT 56
FIGURE 20 GILEAD SCIENCES, INC.: FINANCIAL OVERVIEW 59
FIGURE 21 GILEAD SCIENCES, INC.: SWOT ANALYSIS 60
FIGURE 22 BRISTOL MYERS SQUIBB: FINANCIAL OVERVIEW 63
FIGURE 23 BRISTOL MYERS SQUIBB: SWOT ANALYSIS 64
FIGURE 24 NOVARTIS: FINANCIAL OVERVIEW 67
FIGURE 25 NOVARTIS: SWOT ANALYSIS 68
FIGURE 26 GLAXOSMITHKLINE (GSK PLC): FINANCIAL OVERVIEW 71
FIGURE 27 GLAXOSMITHKLINE (GSK PLC): SWOT ANALYSIS 73
FIGURE 28 AMOYTOP BIOTECH CO., LTD.: FINANCIAL OVERVIEW 76
FIGURE 29 AMOYTOP BIOTECH CO., LTD.: SWOT ANALYSIS 77
FIGURE 30 TIANQING PHARMACEUTICAL GROUP CO., LTD: SWOT ANALYSIS 81
FIGURE 31 SINO BIOPHARMACEUTICAL LIMITED CO., LTD.: FINANCIAL OVERVIEW 84
FIGURE 32 SINO BIOPHARMACEUTICAL LIMITED CO., LTD.: SWOT ANALYSIS 86
FIGURE 33 JIANGSU HANSOH PHARMACEUTICAL CO., LTD. CO., LTD.: FINANCIAL OVERVIEW 89
FIGURE 34 JIANGSU HANSOH PHARMACEUTICAL CO., LTD. CO., LTD.: SWOT ANALYSIS 90
FIGURE 35 AUSPERBIO CO., LTD.: SWOT ANALYSIS 94
FIGURE 36 ASCLETIS BIOSCIENCE CO., LTD. CO., LTD.: SWOT ANALYSIS 98

LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 31
TABLE 2 CHINA HEPATITIS B TREATMENT MARKET, BY DRUG CLASS, 2019–2035 (USD MILLION) 46
TABLE 3 CHINA HEPATITIS B TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD MILLION) 49
TABLE 4 CHINA HEPATITIS B TREATMENT MARKET, BY AGE GROUP, 2019–2035 (USD MILLION) 51
TABLE 5 CHINA HEPATITIS B TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD MILLION) 53
TABLE 6 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL 57
TABLE 7 KEY DEVELOPMENTS 57
TABLE 8 GILEAD SCIENCES, INC.: PRODUCTS OFFERED 59
TABLE 9 GILEAD SCIENCES, INC.: KEY DEVELOPMENTS 60
TABLE 10 BRISTOL MYERS SQUIBB: PRODUCTS OFFERED 63
TABLE 11 BRISTOL MYERS SQUIBB: KEY DEVELOPMENTS 64
TABLE 12 NOVARTIS: PRODUCTS OFFERED 67
TABLE 13 GLAXOSMITHKLINE (GSK PLC): PRODUCTS OFFERED 72
TABLE 14 GSK: KEY DEVELOPMENTS 72
TABLE 15 AMOYTOP BIOTECH CO., LTD.: PRODUCTS OFFERED 76
TABLE 16 TIANQING PHARMACEUTICAL GROUP CO., LTD: PRODUCTS OFFERED 80
TABLE 17 SINO BIOPHARMACEUTICAL LIMITED CO., LTD.: PRODUCTS OFFERED 85
TABLE 18 JIANGSU HANSOH PHARMACEUTICAL CO., LTD. CO., LTD.: PRODUCTS OFFERED 89
TABLE 19 AUSPERBIO CO., LTD.: PRODUCTS OFFERED 93
TABLE 20 ASCLETIS BIOSCIENCE CO., LTD. CO., LTD.: PRODUCTS OFFERED 97